Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

NCT03023904 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT03023904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03023904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
December 29, 2017
Completion date
July 30, 2020
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent non-small cell lung carcinoma, stage iv non-small cell lung cancer